Syndax Pharmaceuticals (SNDX): Weighing the Path to a $39 Target and +135% Upside
Key Takeaways
- The central $39 stock price target is the arithmetic mean of eight verified, current analyst price targets for Syndax Pharmaceuticals, Inc. (SNDX).
- With the stock recently trading near $16.55, reaching $39 implies upside of roughly 135%, a very large move for a clinical-stage biotech.
- Individual analyst targets span a wide range, from $24 (Goldman Sachs) to $57 (Citi), reflecting genuine disagreement about the commercial ramp of Syndax's two approved drugs.
- The strongest supporting factors are FDA approvals for Revuforj (revumenib) in acute leukemias and early commercial traction for Niktimvo (axatilimab).
- The biggest risks are persistent net losses, modest early-stage revenue, and the typical binary volatility of development-stage biotechs.
Breaking Down the Analyst Consensus
Syndax Pharmaceuticals, Inc. (SNDX) focuses on therapies for cancer and related conditions, mainly revumenib (Revuforj) for certain acute leukemias and axatilimab (Niktimvo) for chronic graft-versus-host disease. The central $39 target comes from averaging eight current analyst estimates rather than any single view. Those figures include Citi at $57, Mizuho at $43, Stifel at $40, J.P. Morgan at $40, H.C. Wainwright at $38, Barclays at $35, UBS at $33, and Goldman Sachs at $24. The mean works out to roughly $38.75, rounded to $39. The spread from $24 to $57 is wide, which is typical for pre-profitability biotech names where success probabilities differ sharply. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Overall sentiment leans constructive with most ratings at Buy or Overweight and an S&P Global “Strong Buy” consensus, though recent adjustments show some nuance as firms update models.
Current Levels and the Scale of the Move
Shares have recently changed hands near $16.55, giving a market capitalization around $1.5 billion. Closing the gap to the $39 central target would mean an increase of about 135%, a substantial move by any standard. This is not a modest drift but a scenario where approved products and pipeline progress drive meaningful value creation. Revenue reached roughly $172 million for full-year 2025 and consensus looks for growth to around $315 million in 2026, even as net losses continue. Revuforj has approvals in KMT2A-rearranged and NPM1-mutant acute myeloid leukemia, while Niktimvo is gaining ground in chronic graft-versus-host disease. Commercial execution and further label expansions remain the main drivers cited by analysts.
Factors That Could Support the Target
Key positives include expanded regulatory approvals that widen the addressable market for Revuforj, with revenue scaling quickly from a small base. Niktimvo adds a second commercial product and reduces single-asset dependence. Buy and Overweight ratings dominate coverage, and the put/call ratio has stayed constructive. As losses narrow, a re-rating on price-to-sales multiples could follow, supporting some of the higher targets.
Risks That Could Keep the Target Out of Reach
Syndax is still unprofitable, so the large implied upside assumes continued revenue growth and eventual margin improvement. Biotech valuations can shift quickly on disappointing launches, missed trials, or safety signals—the addition of a QTc prolongation warning to Revuforj’s label is one example already noted by some analysts. Competition in leukemia and graft-versus-host disease markets is increasing, and the wide target range itself shows how analysts can reach different conclusions on the same assets. Macro pressures on higher-risk biotech names can also compress multiples.
Technical Picture and Key Levels
The 52-week range runs from about $12.99 to $25.59. After a significant drawdown into 2026, shares have recovered somewhat but sit well below earlier peaks. The $20–$22 area has acted as resistance, while the low-to-mid teens near the 52-week low have provided support. The $39 target lies far above the recent high, so any move there would require a clear breakout beyond established trading ranges.
Monitoring Points Over the Next Year
Analyst targets typically cover a roughly 12-month horizon. Investors should watch quarterly revenue updates and 2026 guidance, prescription trends for both approved drugs, additional regulatory filings, and any shifts in analyst targets. Broader pipeline readouts and competitive developments in oncology also matter. No single event will settle the debate; the case will build or weaken across multiple quarters.
AI Daily Buy/Sell Signals
I often turn to Tickeron’s AI Daily Buy/Sell Signals when reviewing names like this one. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and market shifts. It serves as a practical complement for timing and momentum checks across a watchlist without replacing independent analysis.
Final Assessment
The question of whether Syndax Pharmaceuticals, Inc. (SNDX) can reach $39 frames a substantial move of roughly 135% from recent levels near $16.55. The $39 figure is simply the average of eight divergent analyst targets, not a promise. The bull case centers on approved products, revenue growth, and potential re-rating as losses ease, while the bear case highlights ongoing losses, execution risks, and competition. Tracking revenue, guidance, regulatory updates, and analyst revisions provides the clearest ongoing view.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
SNDX's RSI Indicator recovers from oversold territory
The RSI Oscillator for SNDX moved out of oversold territory on September 17, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 36 similar instances when the indicator left oversold territory. In 32 of the 36 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNDX advanced for three days, in 223 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
SNDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNDX as a result. In 74 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for SNDX turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 33 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for SNDX entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. SNDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (105.263) is normal, around the industry mean (26.823). P/E Ratio (117.647) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (6.010) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biopharmaceuticals for novel cancer therapies
Industry Biotechnology
Advertisement